We obtained encouraging results that CLT significantly attenuated proteinuria, inflammation, glomerular hypercellularity, and ECM deposition in anti-Thy1.1 nephritis (Fig. 1; Supplementary Figs. 1, 2, 4–9), indicating that CLT was a main contributory ingredient involved in TGV formulations in the treatment of MsPGN. This evidence concerns the gene THY1 and nephritis.